Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Jazz Pharmaceuticals, maintaining a price target of $140.
September 09, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Charles Duncan has reiterated an Overweight rating for Jazz Pharmaceuticals, maintaining a price target of $140. This suggests confidence in the company's stock performance.
The reiteration of an Overweight rating and maintenance of a $140 price target by a reputable analyst suggests a positive outlook for Jazz Pharmaceuticals. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100